Anna D'ANtuono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna D'ANtuono has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Gherli
Translational Hematology and Chemogenomics Laboratory, University of Parma, Italy, Italy
2 shared publications - Bruno Lorusso
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
2 shared publications - Cristina Mecucci
University of Perugia, Perugia, Italy
2 shared publications - Elisa Simoncini
Translational Hematology and Chemogenomics Laboratory, University of Parma, Italy, Italy
2 shared publications - Federico Quaini
Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy
2 shared publications Giannalisa Todaro
Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Italy, Parma, Italy
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (11) , 1423-1439
Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia
Driver mutations in T-cell acute leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for target discovery and therapeutic interventions. In our study, we identified WNK1 as a potential target in T-ALL by pairing a list of vulnerable kinases with data from a phosphoproteomic screen of T-ALL cell lines. We subsequently validated WNK1 by loss-of-function-based studies and tested WNK inhibitors in several in vitro and in vivo T-ALL models and clinical T-ALL samples. We showed that therapeutic WNK1 repression promotes polyploidy, resulting in cell proliferation arrest, and morphometric changes, such as incomplete cell division or chromosome segregation through altered mitotic spindle assembly and abscission defects. Furthermore, we found that WNK1 is overexpressed in the TAL1/2-related subgroup, but not in normal thymus or lymph nodes, suggesting a potential translational area for clinical exploitation in poor-prognosis T-ALL carrying PTEN mutations and del(6q). Our work also reports a functional contribution of WNK1 in the leukemia establishment and progression. Structurally WNK1 is an atypical serine/threonine kinase that diverge from canonical kinases by lacking the conserved lysine in subdomain II, instead featuring a cysteine in subdomain I, which is critical for ATP-binding. This unusual structural configuration creates a distinct ATP-binding pocket with limited sequence similarity to conventional kinases, offering a unique opportunity to develop highly selective small-molecules. Targeting this atypical ATP-domain could thus provide a therapeutic advantage and broaden the treatment landscape for T-ALL.
- 19 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (11) , 1423-1439
Open AccessInhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia
Driver mutations in T-cell acute leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for target discovery and therapeutic interventions. In our study, we identified WNK1 as a potential target in T-ALL by pairing a list of vulnerable kinases with data from a phosphoproteomic screen of T-ALL cell lines. We subsequently validated WNK1 by loss-of-function-based studies and tested WNK inhibitors in several in vitro and in vivo T-ALL models and clinical T-ALL samples. We showed that therapeutic WNK1 repression promotes polyploidy, resulting in cell proliferation arrest, and morphometric changes, such as incomplete cell division or chromosome segregation through altered mitotic spindle assembly and abscission defects. Furthermore, we found that WNK1 is overexpressed in the TAL1/2-related subgroup, but not in normal thymus or lymph nodes, suggesting a potential translational area for clinical exploitation in poor-prognosis T-ALL carrying PTEN mutations and del(6q). Our work also reports a functional contribution of WNK1 in the leukemia establishment and progression. Structurally WNK1 is an atypical serine/threonine kinase that diverge from canonical kinases by lacking the conserved lysine in subdomain II, instead featuring a cysteine in subdomain I, which is critical for ATP-binding. This unusual structural configuration creates a distinct ATP-binding pocket with limited sequence similarity to conventional kinases, offering a unique opportunity to develop highly selective small-molecules. Targeting this atypical ATP-domain could thus provide a therapeutic advantage and broaden the treatment landscape for T-ALL.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (4) , C954-C973
A novel cell indirect calorimetry method unveils the metabolic fluxomic signatures of human monocyte-derived M(LPS + IFN-γ) and M(IL-4) macrophages
We present a novel microcalorimetry-based approach for quantifying metabolic fluxes in human cells. Applied to primary monocyte-derived human macrophages, this method reveals that M(LPS + IFN-γ) and M(IL-4) subsets exhibit distinct fluxomic profiles: the former favors glycolysis, whereas the latter shows enhanced TCA cycle activity and lipid oxidation. These findings resolve previous discrepancies between transcriptomic and functional data and provide a robust framework for investigating immunometabolism in primary human cells.
- 1 April 2026
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 330 (4) , C954-C973
A novel cell indirect calorimetry method unveils the metabolic fluxomic signatures of human monocyte-derived M(LPS + IFN-γ) and M(IL-4) macrophages
We present a novel microcalorimetry-based approach for quantifying metabolic fluxes in human cells. Applied to primary monocyte-derived human macrophages, this method reveals that M(LPS + IFN-γ) and M(IL-4) subsets exhibit distinct fluxomic profiles: the former favors glycolysis, whereas the latter shows enhanced TCA cycle activity and lipid oxidation. These findings resolve previous discrepancies between transcriptomic and functional data and provide a robust framework for investigating immunometabolism in primary human cells.
- Open Access
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML
The overexpression of the ecotropic viral integration site-1 gene (EVI1/MECOM) marks the most lethal acute myeloid leukemia (AML) subgroup carrying chromosome 3q26 abnormalities. By taking advantage of the intersectionality of high-throughput cell-based and gene expression screens selective and pan-histone deacetylase inhibitors (HDACis) emerge as potent repressors of EVI1. To understand the mechanism driving on-target anti-leukemia activity of this compound class, here we dissect the expression dynamics of the bone marrow leukemia cells of patients treated with HDACi and reconstitute the EVI1 chromatin-associated co-transcriptional complex merging on the role of proliferation-associated 2G4 (PA2G4) protein. PA2G4 overexpression rescues AML cells from the inhibitory effects of HDACis, while genetic and small molecule inhibition of PA2G4 abrogates EVI1 in 3q26 AML cells, including in patient-derived leukemia xenografts. This study positions PA2G4 at the crosstalk of the EVI1 leukemogenic signal for developing new therapeutics and urges the use of HDACis-based combination therapies in patients with 3q26 AML.
- 4 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Open AccessOrthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML
The overexpression of the ecotropic viral integration site-1 gene (EVI1/MECOM) marks the most lethal acute myeloid leukemia (AML) subgroup carrying chromosome 3q26 abnormalities. By taking advantage of the intersectionality of high-throughput cell-based and gene expression screens selective and pan-histone deacetylase inhibitors (HDACis) emerge as potent repressors of EVI1. To understand the mechanism driving on-target anti-leukemia activity of this compound class, here we dissect the expression dynamics of the bone marrow leukemia cells of patients treated with HDACi and reconstitute the EVI1 chromatin-associated co-transcriptional complex merging on the role of proliferation-associated 2G4 (PA2G4) protein. PA2G4 overexpression rescues AML cells from the inhibitory effects of HDACis, while genetic and small molecule inhibition of PA2G4 abrogates EVI1 in 3q26 AML cells, including in patient-derived leukemia xenografts. This study positions PA2G4 at the crosstalk of the EVI1 leukemogenic signal for developing new therapeutics and urges the use of HDACis-based combination therapies in patients with 3q26 AML.